17 September 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Lundbeckfond Invest announces the result of the voluntary exchange offer to eligible shareholders in Lundbeck

Lundbeckfond Invest A/S (**Lundbeckfond Invest**), a fully owned subsidiary of the Lundbeck Foundation, today announces the result of the voluntary exchange offer to holders of A-shares in H. Lundbeck A/S (**Lundbeck**).

The offer period expired yesterday, 16 September 2026, and the settlement process will now be initiated and completed as soon as possible in accordance with the terms and conditions of the exchange offer.

Lundbeckfond Invest has received valid acceptances representing a total of 23,666,150 A-shares corresponding to approximately 12% of the A share capital of Lundbeck in exchange of a total of 23,666,150 existing B-shares currently owned by Lundbeckfond Invest corresponding to approximately 3% of the B share capital of Lundbeck.

Following settlement, Lundbeckfond Invest will own 183,761,677 A-shares and 502,997,913 B-shares in Lundbeck. This represents approximately 92% of the total A-shares and 63% of the total B-shares in Lundbeck and corresponds to approximately 84% of the total voting rights and 69% of the total share capital in Lundbeck.

”We are pleased with the positive response from other A-shareholders who have taken this opportunity to consolidate their ownership in the more liquid B-share class. We remain committed to supporting the development of Lundbeck as we have done through more than 70 years of stable ownership,” says Lene Skole, CEO at the Lundbeck Foundation.

As communicated in connection with the announcement of the exchange offer, Lundbeckfond Invest may, in collaboration with Lundbeck, explore the potential for a de-listing of the A-share class from Nasdaq Copenhagen with a view that only one share class in Lundbeck is being publicly traded.

The figures remain subject to final verification and completion of the settlement process. In the event of material changes in the final result of the exchange offer, Lundbeckfond Invest will make relevant announcements.

Additional information and details on the settlement process are, subject to certain restrictions, available at www.lundbeckfonden.com/exchangeoffer.

Contact
Kasper Riis
Head of Communications
+45 21 39 89 80

The Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of enterprise and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner, both majority and minority, of several international healthcare companies – Lundbeck, Falck, ALK-Abello, Ferrosan Medical Devices, Ellab and WSA – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. By 2030, the Foundation aims to increase its average annual grants to at least DKK 1bn primarily focusing on the brain – including the world's largest brain research prize, The Brain Prize.

None of the securities referred to herein have been or will be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable other securities laws. There will not be any public offering of any of the securities in the United States.

In the United Kingdom, this press release is directed only at, and communicated only to, persons who are "qualified investors" within the meaning of paragraph 15 of Part 2 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024 and who are (i) persons who fall within the definition of "investment professional" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) persons who fall within article 49(2)(a) to (d) of the Order, or (iii) persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as "Relevant Persons"). This press release must not be acted on or relied on by persons in the UK who are not Relevant Persons.

This press release contains forward-looking statements that reflect the Foundation's current view of future events. Words such as "intend", "assess", "expect", "may", "plan", "estimate" and other expressions involving indications or predictions regarding future development or trends, not based on historical facts, identify forward-looking statements and reflect the Foundation's beliefs and expectations and involve a number of risks, uncertainties and assumptions which could cause actual events and performance to differ materially from any expected future events or performance expressed or implied by the forward-looking statement. The information contained in this press release is subject to change without notice and, except as required by applicable law, the Foundation does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it and nor does it intend to. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.